# Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

> **NCT02204904** · — · TERMINATED · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 59 (actual)

## Conditions studied

- X-Linked Adrenoleukodystrophy (X-ALD)
- Cerebral Adrenoleukodystrophy (CALD)
- Adrenoleukodystrophy (ALD)

## Interventions

- **GENETIC:** Allo-HSCT

## Key facts

- **NCT ID:** NCT02204904
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2019-12-06
- **Final completion:** 2019-12-06
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Sufficient enrollment for Month 24 safety and efficacy endpoints
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204904, "Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02204904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*